LENZ Therapeutics, Inc. (LENZ) Misses Q3 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
Tweet
Share
E-mailGet Alerts LENZ Hot Sheet
Join SI Premium – FREE
LENZ Therapeutics, Inc. (NASDAQ: LENZ) reported Q3 EPS of ($0.99), $0.08 worse than the analyst estimate of ($0.91). Revenue for the quarter came in at $3.38 million versus the consensus estimate of $4.5 million.
For earnings history and earnings-related data on LENZ Therapeutics, Inc. (LENZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TotalEnergies SE (TTE) Tops Q3 EPS by 43c
- Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) Tops Q3 EPS by 100c
- Lennox International (LII) PT Lowered to $350 at Mizuho
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
